Siemens Healthineers Adds Pathway for Lung Cancer to its AI-based Clinical Decision Support Software

Siemens HealthineersSiemens Healthineers presents its second pathway for its AI-Pathway Companion(1) at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process(2). The AI-Pathway Companion Lung Cancer(3) assists multidisciplinary teams (MDT) by facilitating patient management and case reviews in a single dashboard, providing quality checks on data completeness, and enabling the documentation of clinically relevant patient-specific notations. "During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available. These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that the right set of information is available, would substantially increase efficiency," says Prof. Mathias Prokop, Head of the department Radiology, Nuclear Medicine and Anatomy, Radboud University Nijmegen(4).

AI-Pathway Companion

Siemens Healthineers adds the pathway for lung cancer for its AI-Pathway Companion to the already existing CE-marked pathway for prostate cancer. The software is designed to help in advanced oncology care by integrating contextualized data along the patient pathway. Utilizing the full pathway with all available data(2), healthcare professionals can optimize the treatment for the individual patient and adherence to evidence-based standards of care is easier to accomplish(5). This transparency also helps collaboration across departments and cancer boards. Everyone involved always has the full picture and can contribute to the treatment discussion with their specific knowledge. "The introduction of the AI-Pathway Companion Lung Cancer demonstrates our continued commitment to supporting healthcare providers in their transformation to value-based healthcare. With the AI-Pathway Companion solution, we are presenting a next-gen clinical decision support system; we want to continue trail blazing in this market by partnering with key customers on future innovation," says Wido Menhardt, Head of Digital Health at Siemens Healthineers.

Through ongoing development and refinement of data interfaces, Siemens Healthineers aims to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. The company looks forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.

About Siemens Healthineers AG

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide.

1. AI-Pathway Companion consists of several health products and medical devices in their own right, and products under development. AI-Pathway Companion is not commercially available in all countries. Their future availability cannot be guaranteed.
2. All data is available as required per guideline. Feature dependent on quality of input data.
3. AI-Pathway Companion Lung Cancer VA10A supports Singlenprimary tumor. AI-Pathway Companion Lung Cancer VA10A supports Nonsmallncell Lung cancer cases only.
4. Dr. Mathias Prokop is employed by an institution that receives financial support from Siemens Healthineers for collaborations.
5. All data is available as required per guideline. Feature dependent on quality of input data. AI-Pathway Companion Lung Cancer VA10A supports NCCN guidelines. Customer shall ensure that guidelines are applicable and appropriate as per the local site policies and procedures and access to procedures.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...